ELISA Kit for Asymmetrical Dimethylarginine (ADMA)

12.35-1, 000ng/mL

The minimum detectable dose of this kit is typically less than 4.99ng/mL

2h

This assay has high sensitivity and excellent specificity for detection of Asymmetrical Dimethylarginine (ADMA).
No significant cross-reactivity or interference between Asymmetrical Dimethylarginine (ADMA) and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

This assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Asymmetrical Dimethylarginine (ADMA) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Asymmetrical Dimethylarginine (ADMA) and unlabeled Asymmetrical Dimethylarginine (ADMA) (Standards or samples) with the pre-coated antibody specific to Asymmetrical Dimethylarginine (ADMA). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Asymmetrical Dimethylarginine (ADMA) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Asymmetrical Dimethylarginine (ADMA) in the sample.

Interactions among Vascular-Tone Modulators Contribute to High Altitude Pulmonary Edema and Augmented Vasoreactivity in Highlanders; Effect of CCL5 on dimethylarginine dimethylaminohydrolase-1 production in vascular smooth muscle cells from spontaneously hypertensive rats.; Effect of 18β-glycyrrhetinic acid on cerebral vasospasm caused by asymmetric dimethylarginine after experimental subarachnoid hemorrhage in rats.; Correlation research on ADMA plasma levels and left ventricular function of peritoneal dialysis patients; Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with COPD; Dimethylarginine dimethylaminohydrolase-1 mediates inhibitory effect of interleukin-10 on angiotensin II-induced hypertensive effects in vascular smooth muscle cells of spontaneously hypertensive rats; Effect of 18β-glycyrrhetinic acid on cerebral vasospasm caused by asymmetric dimethylarginine after experimental subarachnoid hemorrhage in rats; Dimethylarginine Dimethylaminohydrolase 2 (DDAH 2) Gene Polymorphism, Asymmetric Dimethylarginine (ADMA) Concentrations, and Risk of Coronary Artery Disease: A Case-Control Study; Increased serum concentrations of asymmetric dimethylarginine (ADMA) in patients with early-onset coronary artery disease.; Asymmetric dimethylarginine (ADMA) elevation and arginase up-regulation contribute toendothelial dysfunction related to insulin resistance in rats and morbidly obese humans.; Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).; A Novel Role of Irbesartan in Gastroprotection against Indomethacin-Induced Gastric Injury in Rats: Targeting DDAH/ADMA and EGFR/ERK Signaling; Multivessel analysis of progressive vascular aging in the rat: Asynchronous vulnerability among vascular territories; Arginine bioavailability and endothelin-1 system in the regulation of vascular function of umbilical vein endothelial cells from intrauterine growth restricted newborns; Probucol improves erectile function via Activation of Nrf2 and coordinates the HO-1/DDAH/PPAR-γ/eNOS pathways in streptozotocin-induced diabetic rats; Demographic, clinical and lifestyle predictors for severity of erectile dysfunction and biomarkers level in Malaysian patients; Novel cellularly active inhibitor regresses DDAH1 induced prostate tumor growth by restraining tumor angiogenesis through targeting DDAH1/ADMA/NOS pathway;